TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of “Moderate Buy” from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $102.00.

TMDX has been the subject of a number of analyst reports. Oppenheimer lifted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler began coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price target on the stock. Finally, Morgan Stanley lifted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $87.86 on Thursday. The firm’s 50 day simple moving average is $83.01 and its 200 day simple moving average is $72.88. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $99.63. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -114.10 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. During the same period in the prior year, the company earned ($0.21) earnings per share. The company’s revenue for the quarter was up 158.6% compared to the same quarter last year. As a group, sell-side analysts forecast that TransMedics Group will post -0.14 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 2,330 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 2,330 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the sale, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold 115,408 shares of company stock worth $9,802,401 in the last 90 days. Company insiders own 6.70% of the company’s stock.

Institutional Trading of TransMedics Group

Large investors have recently made changes to their positions in the company. FMR LLC lifted its stake in TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the last quarter. BlackRock Inc. boosted its stake in TransMedics Group by 2.4% in the second quarter. BlackRock Inc. now owns 2,309,393 shares of the company’s stock valued at $193,943,000 after buying an additional 54,776 shares in the last quarter. Vanguard Group Inc. grew its position in TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after acquiring an additional 50,673 shares during the last quarter. Eventide Asset Management LLC grew its position in TransMedics Group by 7.4% in the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC raised its stake in TransMedics Group by 71.9% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock worth $59,083,000 after acquiring an additional 400,255 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.